Antihypoxic tool

 

(57) Abstract:

The tool is aimed at improving the endurance of the organism to hypoxia, prevention of hypoxic tissue damage and full recovery of homeostasis system of energy supply of the cells in the pathology when it is hypoxic and ischemic lesions. The drug was tested on the model of hypobaric hypoxia generated in a pressure chamber at a height of 11.5 thousand meters (when hoisting speed 50 m/s, without absorption of CO2. It is established that the tool can dramatically increase the time to spare and the coefficient for the protection of animals from hypoxia. The effect is many times greater than the protective effects of known antihypoxants, for example, sodium oxybutyrate and Ankara. The tool contains (wt.h.) derivatives flavina involved in tissue redox processes of 0.2-20.0, coenzyme Q10- 1,0-10,0, OVER - 0,5-10,0, cytochrome C - 5,0-20,0, inosine - 60,0-92,0. It is assumed that the developed tool will be widely used to increase resistance and protect the body from hypoxia and as a means of substitution therapy in ischemia and hypoxia and open up new approaches in the treatment of these conditions. 1 table, 4 C.p. f-crystals.

The image is, Cana to hypoxia by preventing disturbances of the homeostasis of energy systems and restoration in pathology, ischemic and hypoxic cell damage.

The purpose of the invention to develop a combined balanced drug, combination of ingredients which provides a sustainable increase of protective properties of the organism to hypoxia, increases its backup capabilities in maintaining (protection) and the complete restoration of homeostatic state system of energy supply of the cells has a protective and therapeutic effect.

The goal is achieved by including in the composition a pharmaceutical flavina (flavinadeninnukleotid (FAD) or playmonopolyonline (FMN) or their predecessor Riboflavin, vzaimoprevrascheny in the body, or a derivative of the last benzoflavone also becoming necessary flavins), coenzyme Q10(ubiquinone) and dinucleotide (NAD), cytochrome C, inosine in the proportions, by weight.h. derivatives flavina involved in tissue redox processes of 0.2-20.0, coenzyme Q10- 1,0-10,0, OVER 0.5 to 10.0, cytochrome C 5,0-20,0, inosine 60,0-92,0.

Aspnum substrate (in hypoxic and ischemic conditions the content of glycogen in the tissue falls).

The basis of the developed combined drug is the harmonious interaction of all the ingredients (not the simple summation of the effects), indicating the drug is a brand new property, not possessed by any one of the ingredients separately, simultaneously working on different key parts of energy systems, prevents disturbance of the homeostasis of the system and ensure its sustainable recovery.

FAD (0.3 mg/kg, or FMN 0.6 mg/kg, or Riboflavin 2 mg/kg, or benzoflavone 5 mg/kg), coenzyme Q10(2 mg/kg), ABOVE (0.5 mg/kg), cytochrome C (10 mg/kg), inosine (80 mg/kg) were mixed and dissolved immediately before use at a temperature of 38-40oC and thoroughly mixing a 40% solution of glucose or saline solution.

Example. The study was carried out on outbred rats weighing 200-250 g were divided into highly stable (WU) and discostick (WELL) to acute oxygen deficiency. Antihypoxic activity of the combined funds of its prototype and reference tools was studied on a model of acute gipobaricheskoi hypoxia, combined with hypercapnia animals raised to a height of 11.5 thousand meters with a speed of 50 m/s E. The first group consisted of animals that were introduced developed preparat, the second GHB (gamma-hydroxy butyric acid), commonly used as a reference antihypoxic tools.

Antihypoxic drug was administered to the animals intraperitoneally for 40 minutes to rise in the chamber. Registered duration of survival (standby time in min) BWon "high" until the second agonal breath.

The research results are summarized in the table. They demonstrate that the proposed remedy in the case of animal WELL to hypoxia increases INW8.6 times more than GHB. This gives the ratio increased protection to hypoxia 39.5 times, and Gamka just 4.6. It should be noted that the proposed means for both parameters was more pronounced in the case of animals WU to hypoxia.

The increase in the concentration of ingredients flavinadeninnukleotid to 10 mg/kg, coenzyme Q10up to 10 mg/kg did not significantly alter the effect. The decline of the content of the FAD, and coenzyme Q10below 0.3 and 1 mg/kg, respectively, decreases INWto 45.5 minutes

Thus, the developed tool, the use of which should be considered as lower toxicity, and to increase the resistance (protection) of the organism to hypoxia and new approaches in the treatment of hypoxic and ischemic conditions.

It is assumed that the developed tool will be widely used to improve the endurance of the organism, tissue hypoxia, and performance under extreme conditions in space and at great depths, as well as in the treatment of brain ischemia, infarction and other ischemic and hypoxic conditions of tissues and organs.

1. Antihypoxic agent containing cytochrome C, characterized in that it further comprises derivatives flavina involved in tissue redox processes, coenzyme Q10, nicotinamide adenine dinucleotide, inosine in the proportions, by weight.h.

Derivatives flavina involved in tissue redox processes 0,2 20,0

Coenzyme Q101,0 10,0

Nicotinamide adenine dinucleotide 0,5 10,0

Cytochrome C 5,0 20,0

Inosine 60,0 92,0

2. Means under item 1, characterized in that as flavina contains playmonopolyonline 0.5 to 20.0 wt.h.

3. Means under item 1, characterized in that as flavina contains Riboflavin 2.0 to 10.0 wt.h.

4. Means under item 1, characterized in that as flavina contains benzoflavone 2.0 to 20.0 wt.h.

5. Means under item 1, characterized in that

 

Same patents:
The invention relates to medicine and, more specifically, to ophthalmology, and can be used in surgical treatment of patients with glaucoma

Eye drops // 2088215
The invention relates to medicine, in particular to ophthalmology, and can be used in the treatment of traumatic injuries, trophic disorders and chemical burns of the conjunctiva, cornea, skin
The invention relates to medicine and can be used to treat wounds, burns, trophic ulcers, etc
The invention relates to methods cooking basics of nutrient media used, for example, in veterinary medicine and other fields
The invention relates to methods cooking basics of nutrient media used, for example, in veterinary medicine and other fields
The invention relates to medicine, in particular to methods for medicinal products for cosmetics and treatment of wounds, trophic ulcers
The invention relates to medicine and can be used in addiction treatment for AAS

The invention relates to the chemistry of natural compounds, specifically to obtain protein hydrolysate from immunologically immature tissue, which is used as burns funds
The invention relates to cardiology, in particular to the development of a drug to overcome the refractoriness of the failure of the heart in inflammatory lesions of the myocardium and full recovery subcellular systems responsible for the act of contraction-relaxation of cardiomyocytes
The invention relates to medicine, cardiology, in particular to the development of a medicinal product for full balanced recovery of power supply to the myocardium

The invention relates to the production of Riboflavin (vitamin B2)

The invention relates to medicine, particularly cardiology

The invention relates to medicine and relates to a tool for the treatment of stomatitis

The invention relates to wound-healing and anti-inflammatory agent and can be used for the treatment of wounds, ulcers and burns of the mucous membranes and skin

The invention relates to derivatives of 5-(substituted amino)-1,2,4-triazolo[1,5-a] pyrimidine according to the present invention correspond to the General formula (I):

,

this includes their pharmaceutically acceptable acid salt additive, in which - Q - piperidinyl, morpholinopropan, piperazinone optionally substituted C1-4-alkyl or a group of formula S(0)pR3where p is 0, 1 or 2, and R3- straight or branched C1-8alkyl, C2-6alkenyl or phenyl-(C1-4-alkyl), the latter may bear one or more halogen or nitro substituents; or a group of the form NR4R5where R4and R5each represent hydrogen, straight or branched C1-10-alkyl, C2-6alkenyl, phenyl-(C1-4alkyl) or di(C1-4alkyl)-amino-(C1-6alkyl); R1and R2each represent hydrogen or straight or branched C1-4alkyl, or R1and R2together form a group of the formula (CH2)n-Y-(CH2)mwhere Y is CH2group, a sulfur atom or a group of the formula NR6where R6denotes phenyl (C1-4alkyl), n and m each represents O, 1, 2, 3, 4, or 5; Z is a group of the formula NRmantel or phenyl-(C1-4alkyl), the latter may bear one or more substituents selected from the group consisting of halogen, hydroxy, C1-4of alkyl, C1-4alkoxy, amino and nitro; and (C1-4alkyl)-amino-(C1-6alkyl), di(C1-4alkyl)-amino-(C1-6alkyl or C1-6-alkyl, the latter may be substituted by hydroxy, amino, carboxy, morpholine-carbonyl, 4-(2-hidroxietil)-piperazine-1-yl-carbonyl, (C1-4alkoxy)-carbonyl or-5 - or 6-membered saturated or unsaturated heterocyclic group containing one or more nitrogen atoms and/or oxygen, and possibly compressed in the benzene ring; or R7to R8together form a group of the formula (CH2)j-W-(CH)2K, where j and K each represent 1, 2 or 3, and W is oxygen, CH2, CHOH or a group of the formula NR10in which R10is hydrogen, C1-4alkoxycarbonyl or C1-4alkyl, the latter, perhaps, is the Deputy selected from the group consisting of hydroxy and phenyl; or a group of the formula SR9in which R9- C1-4alkyl, substituted (C1-4alkoxy)-carbonyl, provided that if Q is hydrogen or a group of formula S(0)PR3, R1and R2- no not hydrogen or C1-4alkyl, and

The invention relates to medicine and biology and refers to drugs that stimulate DNA synthesis
The invention relates to medicine, namely to Oncology
The invention relates to medicine, namely to Oncology, and can be used in the treatment of patients with locally advanced cancers

The invention relates to medicine, in particular to Phthisiology
Up!